<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We established a photothrombotic occlusion model in the guinea pig middle cerebral artery </plain></SENT>
<SENT sid="1" pm="."><plain>In this model, the middle cerebral artery was recanalized within 10 to 20 min after thrombotic occlusion, with subsequent cyclic flow reductions </plain></SENT>
<SENT sid="2" pm="."><plain>Cyclic flow reductions in the middle cerebral artery are expected to manage <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> by modulating arterial patency </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we evaluated the effect of several antiplatelet agents on the frequency of cyclic flow reductions and subsequent <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> using this model </plain></SENT>
<SENT sid="4" pm="."><plain>A platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, ME3277 (<z:chebi fb="199" ids="26708">sodium</z:chebi> hydrogen [4-[(4,5,6,7-tetrahydrothieno[3,2c]<z:chebi fb="0" ids="51641">pyridin-2-yl</z:chebi>) carbonylamino] <z:chebi fb="9" ids="46887">acetyl</z:chebi>-<z:chebi fb="0" ids="35448">o-phenylene</z:chebi>] dioxydiacetate, 0.3, 1 and 3 mg/kg i.v.) dose-dependently inhibited the ex vivo platelet aggregation induced by <z:chebi fb="13" ids="16761">ADP</z:chebi> (5 microM), collagen (0.8 and 20 microg/ml) and <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> (100 microM) </plain></SENT>
<SENT sid="5" pm="."><plain>While the same doses of ME3277 reduced the frequency of the cyclic flow reductions and increased the total patency time of the middle cerebral artery, time to thrombotic occlusion was prolonged only at the highest dose, 3 mg/kg </plain></SENT>
<SENT sid="6" pm="."><plain>ME3277 (0.3-3 mg/kg) significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and improved the neurological deficit at 24 h </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, aspirin (30 mg/kg) did not affect these variables in spite of complete inhibition of platelet aggregation induced by <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> and collagen (0.8 microg/ml) </plain></SENT>
<SENT sid="8" pm="."><plain>A <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> synthetase inhibitor, <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel, significantly increased the total patency time and reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume at 30 mg/kg </plain></SENT>
<SENT sid="9" pm="."><plain>Inhibition of <z:chebi fb="0" ids="15552">prostaglandin I2</z:chebi> generation could explain the effectiveness of <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel but not aspirin in this model </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> are more beneficial than aspirin for the treatment of <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> </plain></SENT>
</text></document>